EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Osimertinib for EGFR ‐Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First‐Generation EGFR ‐ TKI Resistance

Yidan Zhang, Yingqi Xu iD, Jianlin Xu, Hua Zhong, Jinjing Xia, Runbo Zhong iD

Cancer Science · 2025

DOI: 10.1111/cas.16437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yidan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) is the standard therapy for patients harboring T790M after first‐generation EGFR‐TKI resistance. However, the impact of acquired EGFR amplification on the efficacy of third‐generation EGFR‐TKI against T790M remains uncertain. We aimed to investigate whether the presence of acquired EGFR amplification after first‐generation EGFR‐TKI resistance influences the efficacy of third‐generation EGFR‐TKI in patients with advanced non‐small‐cell lung cancer (NSCLC). We reviewed data from 275 advanced NSCLC patients harboring T790M after first‐generation EGFR‐TKI resistance. Patients were categorized into two groups based on the presence or absence of acquired EGFR amplification identified through next‐generation sequencing (NGS) after first‐line EGFR‐TKI treatment. We evaluated the efficacy of osimertinib used as a second‐line treatment. Among these patients, 59 exhibited acquired EGFR amplification, while 216 did not. The median progression‐free survival (PFS) was 12.20 months in the EGFR amplification group and 12.03 months in the non‐amplification group ( p = 0.011), with median overall survival (OS) of 33.90 months and 23.30 months, respectively ( p = 0.164). Multivariate analysis of PFS revealed that acquired EGFR amplification and EGFR 19del were independent prognostic factors for patients with T790M undergoing osimertinib. Additionally, subgroup analysis indicated a prolonged PFS in patients with EGFR 19del compared to those with EGFR 21L858R ( p = 0.034) in the EGFR amplification group. Following first‐generation EGFR‐TKI resistance, advanced EGFR‐mutant NSCLC patients harboring both acquired T790M and EGFR amplification are likely to experience enhanced PFS with osimertinib. This phenomenon is particularly noteworthy among individuals with EGFR 19del.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsHumansErbB ReceptorsFemaleMaleMiddle AgedAgedMutationGene AmplificationAdultAged, 80 and overProgression-Free SurvivalRetrospective StudiesHigh-Throughput Nucleotide SequencingAntineoplastic AgentsIndolesPyrimidines

Stichwörter der Autor:innen

EGFREGFR amplificationEGFR‐TKINSCLCT790M

Substanzen

osimertinibErbB ReceptorsAniline CompoundsAcrylamidesProtein Kinase InhibitorsEGFR protein, humanAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Yingqi Xu, Runbo Zhong

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Xu, Y., Xu, J., Zhong, H., Xia, J., & Zhong, R. (2025). Osimertinib for EGFR ‐Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First‐Generation EGFR ‐ TKI Resistance. Cancer Science. https://doi.org/10.1111/cas.16437

Vancouver

Zhang Y, Xu Y, Xu J, Zhong H, Xia J, Zhong R. Osimertinib for EGFR ‐Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First‐Generation EGFR ‐ TKI Resistance. Cancer Science. 2025. doi:10.1111/cas.16437

BibTeX
@article{Zhang2025,
  author = {Zhang, Yidan and Xu, Yingqi and Xu, Jianlin and Zhong, Hua and Xia, Jinjing and Zhong, Runbo},
  title = {Osimertinib for EGFR ‐Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First‐Generation EGFR ‐ TKI Resistance},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.16437}
}
Kostenlos starten →